DONATE
Eli Lilly announced plans for a $7-billion merger with Centessa, a biotech company specializing in wakefulness drugs aimed at treating Narcolepsy.
Lauren Chapman / Indiana Public BroadcastingEli Lilly announced Tuesday that it will acquire drug company Centessa for more than $7-billion.
The company specializes in drugs to treat daytime sleepiness and other neurological disorders.
Centessa is in the clinical stages of producing a new class of medicines to treat “impaired wakefulness” or narcolepsy.
A small portion of Americans suffer from narcolepsy, but the research could eventually be used to address sleepiness as a side effect of diseases like Alzheimer’s, which is a focus for Eli Lilly.
The biotech company Centessa has headquarters in Boston and London and does not yet have drugs on the market.
The deal nets Centessa $6.3 billion up front. If the U.S. ultimately approves Centessa’s drugs, Lilly will pay an additional $1.5 billion to the company.
Centessa shareholders still have to approve the merger. That move is not expected until later in the year.
A spokesperson with Eli Lilly declined to comment on this story.
Contact Government Reporter Benjamin Thorp at bthorp@wfyi.org
Support WFYI. We can't do it without you.